

HLIB Research

PP 9484/12/2012 (031413)

Tan J Young jytan@hlib.hongleong.com.my (603) 2083 1721


BUY (Maintain)

larget Price:	KW4.15
Previously:	RM3.88
Current Price:	RM3.82
Capital upside	8.6%
Dividend yield	0.8%
Expected total return	9.4%

Sector coverage: Technology

Company description: Frontken is a leading surface engineering service provider in semiconductor and O&G markets.

Share price



Stock information

Bloomberg ticker	FRCB MK
Bursa code	0128
Issued shares (m)	1,572
Market capitalisation (RM m)	5,834
3-mth average volume ('000)	5,606
SC Shariah compliant	Yes
F4GBM Index member	N/A
ESG rating	*
· ·	

Major shareholders

15.6%
15.0%
2.6%

Earnings summary

FYE (Dec)	FY20	FY21f	FY22f
PATMI - core (RM m)	82.7	100.8	122.5
EPS - core (sen)	5.2	6.4	7.8
P/E (x)	73.0	59.9	49.3

Frontken Corporation

Outdid itself again

9M21 core net profit of RM74m (+27% YoY) matched ours but missed street. Top and bottom line growths were mainly driven by semiconductor business though O&G business has seen robust improvement. AGTC has completed the acquisition of a building (Plant 2) situated in the Southern Taiwan Science Park at Kaohsiung City on 9 Jul 2021 to support a major customer's aggressive expansion. It is expected to be commissioned sometimes in 2H22. Reiterate BUY with higher TP of RM4.15, pegged to 50x of mid-FY23 EPS. We like its unique exposure to leading-edge semiconductor frontend supply chain.

Matched ours but missed consensus. All-time high 3Q21 core net profit of RM27m (+3% QoQ, +22% YoY) brought 9M21's total to RM74m (+27% YoY) which was in line with HLIB full year forecast at 74% but came below consensus at 69%. 9M21 one-off adjustments include forex gain (+RM389k), PPE disposal gain (+RM22k), PPE written off (-RM3k) and allowance for impairment losses on receivables (+RM139k).

Dividend. None (3Q20: none). YTD DPS 1.5 sen vs 9M20's 1.2 sen. Dividend is traditionally distributed semi-annually.

QoQ. Turnover inched up 7% mainly due to better performances from Malaysia (+13%), Taiwan (+9%) and Philippines (+6%), more than sufficient to offset the declines in Indonesia (-39%) and Singapore (-6%). In turn, core net profit gained 10% to RM27m thanks to efficiency gain as EBITDA margin strengthened 0.7ppt.

YoY. Revenue saw a solid growth of 23% driven by Malaysia (+43%) and Taiwan (+27%), more than sufficient to offset the contractions in Indonesia (-17%), Philippines (-8%) and Singapore (-1%). Filtered down, core earnings rose 22% on the back of stable EBITDA margin.

YTD. Top and bottom lines strengthened by 23% and 27%, respectively thanks to robust semiconductor business. In terms of segmental sales breakdown, Malaysia (+30%) led the pact, followed by Taiwan (+29%), Philippines and Singapore were rather flat and Indonesia was the sole loser (-22%).

Semiconductor. Generated 85% (3Q20: 88%) of group revenue in 3Q21 at RM99m and PAT improved 13% YoY. It has benefited from higher demand and strong orders from one of its customers' advanced nodes chip. The client's aggressive expansion augurs well for Frontken's semiconductor business for years to come. As such, AGTC has completed the acquisition of a building (Plant 2) situated in the Southern Taiwan Science Park at Kaohsiung City on 9 Jul 2021. It is expected to be commissioned sometimes in 2H22.

O&G. Accounted for the remaining 15% of group turnover in 3Q21 at RM18m and PAT improved 333% YoY. Noticed robust improvement due to new orders trickling in from the various umbrella contracts for provision of manpower supply and also mechanical rotating equipment services and parts that it has with Petronas companies. It hopes that momentum will pick up going forward as the soon to be completed new Pengerang facility will be ready to support the contracts in hand.

Forecast. Unchanged.

Reiterate **BUY** with higher TP of **RM4.15** (previously RM3.88), pegged to 50x of mid-FY23 EPS (previously FY22 EPS). We like Frontken for its multi-year growth ahead on the back of: (1) sustainable global semiconductor market outlook, (2) robust fab investment, (3) leading edge technology (7nm and below), and (4) strong balance sheet (net cash of RM282m or 18 sen per share) to supports its Taiwan expansion.

Financial Forecast

Financial Forec	ast										
All items in (RM m) unless other	rwise stated										
Income statement						Quarterly financial s	ummary				
FYE Dec	FY19	FY20	FY21f	FY22f	FY23f	FYE Dec	3Q20	4Q20	1Q21	2Q21	3Q21
Revenue	339.9	368.3	417.0	494.3	550.2	Revenue	94.8	101.0	103.5	108.6	116.6
COGS	(226.2)	(236.2)	(259.7)	(306.3)	(340.2)	COGS	(60.0)	(65.3)	(64.1)	(69.7)	(74.0)
EBITDA	113.7	132.1	157.3	188.0	210.1	EBITDA	34.8	35.8	39.4	38.9	42.6
D&A	(17.8)	(18.4)	(20.3)	(21.4)	(20.2)	D&A	(4.6)	(4.5)	(4.4)	(4.4)	(4.5)
EBIT	95.9	113.7	137.0	166.6	189.9	EBIT	30.3	31.2	35.0	34.5	38.1
Net Interest Income	0.4	0.6	1.5	1.7	1.9	Net Interest Income	0.1	0.1	0.1	0.1	0.0
Associates	0.0	0.0	0.0	0.0	0.0	Associates	0.0	0.0	0.0	0.0	0.0
PBT	96.3	114.3	138.5	168.3	191.8	PBT	30.3	31.3	35.1	34.5	38.1
Tax	(22.0)	(25.9)	(30.5)	(37.0)	(42.2)	Tax	(7.3)	(6.0)		(7.5)	(8.1)
									(10.1)		
Net Profit	74.2	88.3	108.0	131.2	149.6	Net Profit	23.0	25.3	24.9	27.0	30.0
MI	(5.1)	(6.4)	(7.2)	(8.7)	(9.8)	MI	(1.7)	(2.0)	(2.0)	(2.3)	(2.7)
PATAMI	69.2	82.0	100.8	122.5	139.7	PATAMI	21.3	23.3	22.9	24.7	27.3
Exceptionals	1.0	0.7	0.0	0.0	0.0	Exceptionals	0.5	1.0	(0.7)	0.9	(8.0)
Adj PATAMI	70.1	82.7	100.8	122.5	139.7	Adj PATAMI	21.8	24.2	22.2	25.7	26.5
Basic Shares (m)	1,580.0	1,580.0	1,580.0	1,580.0	1,580.0	Basic Shares (m)	1,580.0	1,580.0	1,580.0	1,580.0	1,580.0
Rep EPS (sen)	4.4	5.2	6.4	7.8	8.8	Rep EPS (sen)	1.4	1.5	1.5	1.6	1.7
Adj EPS (sen)	4.4	5.2	6.4	7.8	8.8	Adj EPS (sen)	1.4	1.5	1.4	1.6	1.7
Adj FD EPS (sen)	4.4	5.2	6.4	7.8	8.8	Adj FD EPS (sen)	1.4	1.5	1.4	1.6	1.7
7 kg 1 B E1 G (0011)		0.2	V. 1	1.0	0.0	7 kg 1 B El G (6011)		1.0		1.0	
Balance sheet						Valuation Ratios					
FYE Dec	FY19	FY20	FY21f	FY22f	FY23f	FYE Dec	FY19	FY20	FY21f	FY22f	FY23f
Cash	197.2	290.5	328.4	368.7	442.3	PER (x)	87.3	73.6	59.9	49.3	43.2
Receivables	86.3	103.1	114.2	135.4	150.7	Core PER (x)	86.0	73.0	59.9	49.3	43.2
Inventories	15.1	20.0	21.3	25.2	28.0	FD PER (x)	86.0	73.0	59.9	49.3	43.2
Investment	0.0	0.0	0.0	0.0	0.0	DPS (sen)	1.7	2.7	3.2	3.9	4.4
PPE	145.5	139.0	148.7	157.3	148.1	Net DY (%)	0.4	0.7	0.8	1.0	1.2
Intangibles	33.8	33.8	33.8	33.8	33.8	Book/share (sen)	23.9	27.8	31.0	34.9	39.3
Other Assets	37.9	31.8	31.8	31.8	31.8	P/Book (x)	16.0	13.7	12.3	10.9	9.7
Total Assets	515.7	618.1	678.3	752.1	834.6	FCF/share (sen)	6.8	7.1	5.6	6.4	9.1
Payables	84.0	18.8	21.3	25.2	28.0	FCF yield (%)	1.8	1.9	1.5	1.7	2.4
ST borrowings	0.8	0.0	0.0	0.0	0.0	Mkt Cap	6,035.6	6,035.6	6,035.6	6,035.6	6,035.6
LT borrowings	0.0	0.0	0.0	0.0	0.0	Net Cash(Debt)	196.3	290.5	328.4	368.7	442.3
Other Liabilities	32.1	132.3	132.3	132.3	132.3	EV	5,839.3	5,745.1	5,707.2	5,666.9	5,593.3
Total liabilities	117.0	151.1	153.6	157.4	160.2	EV/EBITDA (x)	51.4	43.5	36.3	30.1	26.6
Shareholders' Funds	377.0	440.0	490.4	551.6	621.5	ROE (%)	18.6	18.8	20.6	22.2	22.5
MI	21.8	27.0	34.3	43.0	52.9		3.5	22.0	21.7	21.0	22.2
						Current Ratio (x)	3.3	20.9	20.7		21.2
Total S/H Equity	398.7	467.0	524.7	594.7	674.4	Quick Ratio (x)				20.0	
Ttl Liab&S/H Funds	515.7	618.1	678.3	752.1	834.6	Interest Cover (x)	126.8	170.4	N/A	N/A	N/A
Cashflow Analysis						Other Ratios					
FYE Dec	FY19	FY20	FY21f	FY22f	FY23f	FYE Dec	FY19	FY20	FY21f	FY22f	FY23f
EBITDA	113.7	132.1	157.3	188.0	210.1	Sales Growth (%)		8.4	13.2	18.5	11.3
Tax Paid	(19.8)	(22.9)	(30.5)	(37.0)	(42.2)	EBITDA Growth (%)		16.2	19.1	19.5	11.7
WC Changes	21.3	11.1	(10.0)	(21.2)	(15.3)	EBIT Growth (%)		18.6	20.5	21.6	14.0
Other	(0.3)	(0.6)	1.5	1.7	1.9	PBT Growth (%)		18.7	21.2	21.5	14.0
CFO	114.9	119.7	118.3	131.5	154.4	Net Profit Growth (%)		19.0	22.3	21.5	14.0
FCF	107.9	112.0	88.3	101.5	143.4	EBITDA Margin (%)	33.4	35.9	37.7	38.0	38.2
CAPEX (CF)	(7.0)		(30.0)	(30.0)	(11.0)	EBIT Margin (%)	28.2	30.9	32.9	33.7	34.5
Acquisitions	(2.6)	(7.7) (0.8)	0.0	0.0	0.0	PBT Margin (%)	28.3	31.0	33.2	34.0	34.9
Other	(2.4)	(3.4)	0.0	0.0	0.0	Net Profit Margin (%)	21.8	24.0	25.9	26.6	27.2
CFI Dividend	(12.1)	(11.9)	(30.0)	(30.0)	(11.0)	Net Debt/Equity (%)	Cash	Cash	Cash	Cash	Cash
Dividend	(18.9)	(28.3)	(50.4)	(61.2)	(69.9)	CAPEX/Sales (%)	2.1	2.1	7.2	6.1	2.0
Debt changes	(10.7)	(0.8)	0.0	0.0	0.0						
Other	(4.2)	(4.8)	0.0	0.0	0.0						
CFF	(33.7)	(33.9)	(50.4)	(61.2)	(69.9)						
Net Cashflow	69.1	73.9	38.0	40.3	73.6						

Figure #1 Quarterly results comparison

FYE Dec (RM m)	3Q20	2Q21	3Q21	QoQ	YoY	9M20	9M21	YoY
Revenue	94.8	108.6	116.6	7.3	23.0	267.3	328.7	23.0
EBITDA	34.8	38.9	42.6	9.5	22.3	96.3	120.9	25.5
EBITDA Margin	36.8	35.8	36.5			36.0	36.8	
EBIT	30.3	34.5	38.1	10.4	25.8	82.4	107.5	30.4
PBT	30.3	34.5	38.1	10.4	25.7	83.0	107.7	29.8
PAT	23.0	27.0	30.0	11.0	30.4	63.1	81.9	29.8
Reported PATMI	21.3	24.7	27.3	10.4	27.9	58.7	75.0	27.7
Core PATMI	21.8	25.7	26.5	3.3	21.6	58.5	74.4	27.3
Reported EPS (sen)	1.4	1.6	1.7	10.4	27.9	3.7	4.7	27.7
Core EPS (sen)	1.4	1.6	1.7	3.3	21.6	3.7	4.7	27.3

Bursa, HLIB Research

Disclaimer

The information contained in this report is based on data obtained from sources believed to be reliable. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, are made as to the accuracy, adequacy, completeness or reliability of the info or opinions in the report.

Accordingly, neither Hong Leong Investment Bank Berhad nor any of its related companies and associates nor person connected to it accept any liability whatsoever for any direct, indirect or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the info or opinions in this publication.

Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. Hong Leong Investment Bank Berhad has no obligation to update its opinion or the information in this report.

Investors are advised to make their own independent evaluation of the info contained in this report and seek independent financial, legal or other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represents a personal recommendation to you.

Under no circumstances should this report be considered as an offer to sell or a solicitation of any offer to buy any securities referred to herein.

Hong Leong Investment Bank Berhad and its related companies, their associates, directors, connected parties and/or employees may, from time to time, own, have positions or be materially interested in any securities mentioned herein or any securities related thereto, and may further act as market maker or have assumed underwriting commitment or deal with such securities and provide advisory, investment or other services for or do business with any companies or entities mentioned in this report. In reviewing the report, investors should be aware that any or all of the foregoing among other things, may give rise to real or potential conflict of interests.

This research report is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this report, unless specifically indicated otherwise, are under copyright to Hong Leong Investment Bank Berhad. This research report and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.

This report may provide the addresses of, or contain hyperlinks to websites. Hong Leong Investment Bank Berhad takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to Hong Leong Investment Bank Berhad own website material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or Hong Leong Investment Bank Berhad website shall be at your own risk.

1. As of 04 November 2021, Hong Leong Investment Bank Berhad has proprietary interest in the following securities covered in this report: (a) -.

2. As of 04 November 2021, the analyst(s) whose name(s) appears on the front page, who prepared this report, has interest in the following securities covered in this report: (a) -.

Published & printed by:

Hong Leong Investment Bank Berhad (10209-W)

Level 28, Menara Hong Leong, No. 6, Jalan Damanlela, Bukit Damansara, 50490 Kuala Lumpur Tel: (603) 2083 1800

Tel: (603) 2083 1800 Fax: (603) 2083 1766

Stock rating guidelines

BUY

Expected absolute return of +10% or more over the next 12 months.

HOLD

Expected absolute return of -10% to +10% over the next 12 months.

SELL

Expected absolute return of -10% or less over the next 12 months.

UNDER REVIEWRating on the stock is temporarily under review which may or may not result to a change from the previous rating.

NOT RATED Stock is not or no longer within regular coverage.

Sector rating guidelines

OVERWEIGHTSector expected to outperform the market over the next 12 months.NEUTRALSector expected to perform in-line with the market over the next 12 months.UNDERWEIGHTSector expected to underperform the market over the next 12 months.

The stock rating guidelines as stipulated above serves as a guiding principle to stock ratings. However, apart from the abovementioned quantitative definitions, other qualitative measures and situational aspects will also be considered when arriving at the final stock rating. Stock rating may also be affected by the market capitalisation of the individual stock under review.